NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RCI Hospitality Holdings, Inc. ("RCI Hospitality Holdings, Inc." or the "Company") (NASDAQ: RICK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RCI Hospitality Holdings, Inc. investors who were adversely affected by alleged securities fraud between December 15, 2021 and September 16, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fortinet, Inc. ("Fortinet, Inc." or the "Company") (NASDAQ: FTNT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortinet, Inc. investors who were adversely affected by alleged securities fraud between November 8, 2024 and August 6, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Avantor, Inc. ("Avantor, Inc." or the "Company") (NYSE: AVTR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avantor, Inc. investors who were adversely affected by alleged securities fraud between March 5, 2024 and October 28, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between November 7, 2024 and September 12, 2025.

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CarMax, Inc. ("CarMax, Inc." or the "Company") (NYSE: KMX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CarMax, Inc. investors who were adversely affected by alleged securities fraud between June 20, 2025 and September 24, 2025.

Warren Buffett's Berkshire Hathaway (NYSE:BRK-B) just made a rather surprising bet on shares of AI titan Alphabet (NASDAQ:GOOG) last quarter.

Vancouver, Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD).

TISI shares decline after Q3 earnings results, but rising revenues, stronger margins and improving segment performance highlight ongoing progress in its transformation plan.

Medtronic (MDT) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.26 per share a year ago.

Stock futures are lower Tuesday morning after major indexes fell sharply to open the week; Home Depot reported lower quarterly profits than analysts had expected; Apple's new iPhone 17 gave the smartphone maker its best month of market share in China in three years; Nvidia stock is moving lower again as investors prepare for the chipmaker's results; and buy now, pay later firm Klarna posted its first earnings report since going public in September. Here's what investors need to know today.

OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025.

Nvidia management expects to benefit from the huge $3-4 trillion in AI infrastructure spending over the next five years. Nvidia's competitive advantage remains solid as it continues to lead in performance and stays ahead of competitors. We believe that Nvidia's software revenue opportunity could also grow as GPU shipments expand.

WULF finally nears my Buy Zone after the recent meltdown, as it also reports robust AI related opportunities and higher multi-year contracted backlog. The company is more than well positioned to monetize their ambitious "target of 250–500 MW critical IT load of new HPC lease signings annually," thanks to the growing HPC capacity. WULF's projected NOI margin of over ~70% is extremely impressive as well, compared to other data center REITs, with it implying its robust top/ bottom-line growth prospects.

BAC targets a 16-18% ROTCE with plans centered on revenue growth, tech-driven efficiency and stronger client engagement.

JPMorgan posts broad-based revenue gains as rising trading, IB activity and wealth strength offset emerging NII pressure from rate cuts.